UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

International journal of molecular sciences, 2020-11, Vol.21 (23), p.8885

2020

Volltextzugriff (PDF)

COVID-19 in Patients with Hematologic Diseases

Biomedicines, 2022-11, Vol.10 (12), p.3069

2022

Volltextzugriff (PDF)

Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms

American journal of hematology, 2019-07, Vol.94 (7), p.E185-E188

2019

Volltextzugriff (PDF)

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms

EJHaem, 2022-05, Vol.3 (2), p.475-479

2022

Volltextzugriff (PDF)

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

The New England journal of medicine, 2013-12, Vol.369 (25), p.2379-2390

2013

Volltextzugriff (PDF)

Germline MPL mutations may be a rare cause of “triple-negative” thrombocytosis

Experimental hematology, 2024-01, Vol.129, p.104127-104127, Article 104127

2024

Volltextzugriff (PDF)

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination

Blood, 2022-11, Vol.140 (Supplement 1), p.6830-6831

2022

Volltextzugriff (PDF)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms

Blood, 2021-11, Vol.138 (Supplement 1), p.3587-3587

2021

Volltextzugriff (PDF)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

Blood, 2022-04, Vol.139 (17), p.2716-2720

2022

Volltextzugriff (PDF)

Second cancers in MPN: Survival analysis from an international study

American journal of hematology, 2020-03, Vol.95 (3), p.295-301

2020

Volltextzugriff (PDF)

Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis

Hematological oncology, 2021-10, Vol.39 (4), p.589-592

2021

Volltextzugriff (PDF)

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Leukemia, 2021-05, Vol.35 (5), p.1490-1493

2021

Volltextzugriff (PDF)

Isolated congenital asplenia: An overlooked cause of thrombocytosis

American journal of hematology, 2022-08, Vol.97 (8), p.1110-1115

2022

Volltextzugriff (PDF)

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Blood, 2020-01, Vol.135 (5), p.381-386

2020

Volltextzugriff (PDF)

Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib

Hematological oncology, 2020-10, Vol.38 (4), p.554-559

2020

Volltextzugriff (PDF)

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Polycythemia Vera or Essential Thrombocythemia Transformed to Myelofibrosis or Acute Myeloid Leukemia: a Single Center Experience

Blood, 2017-12, Vol.130, p.5497-5497

2017

Volltextzugriff (PDF)

Genomic Profiling of Blast Phase in Philadelphia-Negative Myeloproliferative Neoplasms

Blood, 2017-12, Vol.130, p.1652-1652

2017

Volltextzugriff (PDF)

Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Leukemia, 2020-04, Vol.34 (4), p.1208-1209

2020

Volltextzugriff (PDF)

Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls

Blood, 2019-11, Vol.134 (Supplement_1), p.4170-4170

2019

Volltextzugriff (PDF)

Abstract LB256: Type 1 calreticulin mutations in myeloproliferative neoplasms promote glycolysis via intracellular calcium mediated upregulation of GLUT1

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB256-LB256

2023

Volltextzugriff (PDF)

Abstract LB134: Type 1 calreticulin mutations differentially activate the IRE1α-XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.LB134-LB134

2022

Volltextzugriff (PDF)

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

Blood, 2014-12, Vol.124 (21), p.3215-3215

2014

Volltextzugriff (PDF)

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Blood, 2014-12, Vol.124 (21), p.1822-1822

2014

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)

Sprache

Englisch
(26)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Hematology
(14)
Life Sciences & Biomedicine
(12)
Science & Technology
(12)
Humans
(9)
Mutation
(6)
Neoplasms
(6)
Tumors
(5)
Calreticulin - Genetics
(4)
Myeloproliferative
(4)
Oncology
(4)
Follow-Up Studies
(3)
Genes
(3)
Health Aspects
(3)
Janus Kinase 2
(3)
Janus Kinase 2 - Genetics
(3)
Myelofibrosis
(3)
Myeloproliferative Disorders
(3)
Patients
(3)
Receptors, Thrombopoietin - Genetics
(3)
Thrombocytosis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(11)
American Journal Of Hematology
(3)
Cancer Research
(2)
Hematological Oncology
(2)
Leukemia
(2)
Biomedicines
(1)
Blood Cancer Discovery
(1)
Ejhaem
(1)
Experimental Hematology
(1)
International Journal Of Molecular Sciences
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance

COVID-19 in Patients with Hematologic Diseases

Ruxolitinib treatment and risk of B‐cell lymphomas in myeloproliferative neoplasms

Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

Germline MPL mutations may be a rare cause of “triple-negative” thrombocytosis

Risk of Thrombosis in Myeloproliferative Neoplasms after Sars-Cov-2 Vaccination

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms

Second cancers in MPN: Survival analysis from an international study

Acquired von Willebrand syndrome in myeloproliferative neoplasms with extreme thrombocytosis

Platelet count predicts driver mutations' co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis

Isolated congenital asplenia: An overlooked cause of thrombocytosis

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Impaired virus‐specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Polycythemia Vera or Essential Thrombocythemia Transformed to Myelofibrosis or Acute Myeloid Leukemia: a Single Center Experience

Genomic Profiling of Blast Phase in Philadelphia-Negative Myeloproliferative Neoplasms

Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin

Frequency of Thrombosis Is Higher in MPN Patients Who Develop Second Cancer Than in Controls

Abstract LB256: Type 1 calreticulin mutations in myeloproliferative neoplasms promote glycolysis via intracellular calcium mediated upregulation of GLUT1

Type I but Not Type II Calreticulin Mutations Activate the IRE1α/XBP1 Pathway of the Unfolded Protein Response to Drive Myeloproliferative Neoplasms

Abstract LB134: Type 1 calreticulin mutations differentially activate the IRE1α-XBP1 pathway of the unfolded protein response to drive myeloproliferative neoplasms

Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin

In Contemporary Patients with Polycythemia Vera, Rates of Thrombosis and Risk Factors Delineate a New Clinical Epidemiology

Suchergebnisse filtern